BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31938588)

  • 1. The Use of Epidermal Growth Factor Receptor Type 2-Targeting Tyrosine Kinase Inhibitors in the Management of Epidermal Growth Factor Receptor Type 2-Positive Gastric Cancer: A Narrative Review.
    AlMazmomy AM; Al-Hayani MM; Alomari M; Bazi AG
    Cureus; 2019 Dec; 11(12):e6295. PubMed ID: 31938588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.
    Shankaran V; Xiao H; Bertwistle D; Zhang Y; You M; Abraham P; Chau I
    Adv Ther; 2021 Jan; 38(1):707-720. PubMed ID: 33244736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
    Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
    Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
    Bai R; Chen N; Liang T; Li L; Lv Z; Lv X; Cui J
    Front Oncol; 2020; 10():912. PubMed ID: 32793461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment.
    Xiao H; Bertwistle D; Khela K; Middleton-Dalby C; Hall J
    BMC Cancer; 2023 Feb; 23(1):186. PubMed ID: 36823552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
    Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
    Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study.
    Pape M; Vissers PAJ; Dijksterhuis WPM; Bertwistle D; McDonald L; Mostert B; Derks S; Oving IM; Verhoeven RHA; van Laarhoven HWM
    Ther Adv Med Oncol; 2023; 15():17588359231162576. PubMed ID: 36970109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.
    Inokuchi M; Fujimori Y; Otsuki S; Sato Y; Nakagawa M; Kojima K
    Gastroenterol Res Pract; 2015; 2015():796380. PubMed ID: 26000013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer.
    Seo KW; Jeon T; Kim S; Kim SS; Kim K; Suh BJ; Hwang S; Choi S; Ryu S; Min JS; Lee YJ; Jee YS; Chae H; Yang DH; Lee SH
    J Gastric Cancer; 2017 Mar; 17(1):52-62. PubMed ID: 28337363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
    Bang YJ
    J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas.
    Celli R; Colunga M; Patel N; Djekidel M; Jain D
    J Nucl Med Technol; 2016 Dec; 44(4):234-238. PubMed ID: 27789750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.
    Wang Y; He L; Cheng Y
    Clin Transl Oncol; 2018 Feb; 20(2):212-220. PubMed ID: 28681313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted literature review of the global burden of gastric cancer.
    Casamayor M; Morlock R; Maeda H; Ajani J
    Ecancermedicalscience; 2018; 12():883. PubMed ID: 30679950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
    Zhang Z; Xie T; Zhang X; Qi C; Shen L; Peng Z
    Chin J Cancer Res; 2020 Jun; 32(3):287-302. PubMed ID: 32694895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer.
    Kahraman S; Yalcin S
    Onco Targets Ther; 2021; 14():4149-4162. PubMed ID: 34285507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer.
    Yu M; Liang Y; Li L; Zhao L; Kong F
    Transl Oncol; 2023 Mar; 29():101624. PubMed ID: 36652760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.